NeRRe Therapeutics Ltd
Stevenage Bioscience Catalyst
Incubator Building, Gunnels Wood Road
Stevenage
Herts
SG1 2FX
United Kingdom
Tel: 44-0-1438-906-960
Website: http://nerretherapeutics.com/
Email: info@nerretherapeutics.com
About NeRRe Therapeutics Ltd
NeRRe Therapeutics is a UK based clinical-stage company developing a unique portfolio of neurokinin (NK) receptor antagonists for the treatment of common debilitating conditions caused by neuronal hypersensitivity.YEAR FOUNDED:
2012
LEADERSHIP:
Founder and COO: Mike Trower
CEO: Mary Kerr
CLINICAL TRIAL:
Please click here for clinical trial information.
3 articles about NeRRe Therapeutics Ltd
-
NeRRe Therapeutics raises £20 million in a Series B2 financing round
7/7/2021
NeRRe Therapeutics, a clinical-stage company developing orvepitant, its wholly-owned neurokinin-1 antagonist, as a first in class treatment for disabling chronic cough caused by reflex hypersensitivity disorders, announces it has raised an additional £20 million in a Series B2 financing round.
-
NeRRe Therapeutics Appoints Andrew Kay As Chairman Of The Board
9/27/2017
-
NeRRe Therapeutics Raises £23 Million In Oversubscribed Series B Financing Round
1/5/2017